365 related articles for article (PubMed ID: 11017819)
21. Clinical features and risk factors for mortality in Aeromonas bacteremic adults with hematologic malignancies.
Tsai MS; Kuo CY; Wang MC; Wu HC; Chien CC; Liu JW
J Microbiol Immunol Infect; 2006 Apr; 39(2):150-4. PubMed ID: 16604248
[TBL] [Abstract][Full Text] [Related]
22. The molecular epidemiology of Stenotrophomonas maltophilia bacteraemia in a tertiary referral hospital in the United Arab Emirates 2000-2004.
Jumaa PA; Sonnevend A; Pàl T; El Hag M; Amith R; Trad O
Ann Clin Microbiol Antimicrob; 2006 Dec; 5():32. PubMed ID: 17194302
[TBL] [Abstract][Full Text] [Related]
23. Life-threatening hemorrhagic pneumonia caused by Stenotrophomonas maltophilia in the treatment of hematologic diseases.
Mori M; Tsunemine H; Imada K; Ito K; Kodaka T; Takahashi T
Ann Hematol; 2014 Jun; 93(6):901-11. PubMed ID: 24535696
[TBL] [Abstract][Full Text] [Related]
24. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999).
Gales AC; Jones RN; Forward KR; Liñares J; Sader HS; Verhoef J
Clin Infect Dis; 2001 May; 32 Suppl 2():S104-13. PubMed ID: 11320451
[TBL] [Abstract][Full Text] [Related]
25. Clinical importance of Stenotrophomonas maltophilia nosocomial pneumonia due to its high mortality in hemodialysis patients.
Wakino S; Imai E; Yoshioka K; Kamayachi T; Minakuchi H; Hayashi K; Inamoto H; Itoh H
Ther Apher Dial; 2009 Jun; 13(3):193-8. PubMed ID: 19527465
[TBL] [Abstract][Full Text] [Related]
26. Epidemiology of bloodstream infections in patients with haematological malignancies with and without neutropenia.
Chen CY; Tsay W; Tang JL; Tien HF; Chen YC; Chang SC; Hsueh PR
Epidemiol Infect; 2010 Jul; 138(7):1044-51. PubMed ID: 19941686
[TBL] [Abstract][Full Text] [Related]
27. Outbreak of Stenotrophomonas maltophilia bacteremia in allogenic bone marrow transplant patients: role of severe neutropenia and mucositis.
Labarca JA; Leber AL; Kern VL; Territo MC; Brankovic LE; Bruckner DA; Pegues DA
Clin Infect Dis; 2000 Jan; 30(1):195-7. PubMed ID: 10619754
[TBL] [Abstract][Full Text] [Related]
28. The emergence of Stenotrophomonas maltophilia as a significant nosocomial pathogen at the University Hospital of the West Indies.
Nicholson AM; Castle D; Akpaka P; Tennant I; Nelson M
West Indian Med J; 2004 Jan; 53(1):17-22. PubMed ID: 15114888
[TBL] [Abstract][Full Text] [Related]
29. Rates of Stenotrophomonas maltophilia colonization and infection in relation to antibiotic cycling protocols.
Pakyz AL; Farr BM
Epidemiol Infect; 2009 Dec; 137(12):1679-83. PubMed ID: 19874637
[TBL] [Abstract][Full Text] [Related]
30. Pseudooutbreak of Stenotrophomonas maltophilia bacteremia in a general ward.
Park YS; Kim SY; Park SY; Kang JH; Lee HS; Seo YH; Cho YK
Am J Infect Control; 2008 Feb; 36(1):29-32. PubMed ID: 18241733
[TBL] [Abstract][Full Text] [Related]
31. Non-susceptibility trends among Pseudomonas aeruginosa and other non-fermentative Gram-negative bacteria from bacteraemias in the UK and Ireland, 2001-06.
Livermore DM; Hope R; Brick G; Lillie M; Reynolds R;
J Antimicrob Chemother; 2008 Nov; 62 Suppl 2():ii55-63. PubMed ID: 18819980
[TBL] [Abstract][Full Text] [Related]
32. Which patient is a candidate for empirical therapy against Stenotrophomonas maltophilia bacteraemia? An analysis of associated risk factors in a tertiary care hospital.
Metan G; Hayran M; Hascelik G; Uzun O
Scand J Infect Dis; 2006; 38(6-7):527-31. PubMed ID: 16798705
[TBL] [Abstract][Full Text] [Related]
33. Risk Factors Associated with Stenotrophomonas maltophilia Bacteremia: A Matched Case-Control Study.
Sumida K; Chong Y; Miyake N; Akahoshi T; Yasuda M; Shimono N; Shimoda S; Maehara Y; Akashi K
PLoS One; 2015; 10(7):e0133731. PubMed ID: 26208218
[TBL] [Abstract][Full Text] [Related]
34. Bacteremia caused by Capnocytophaga species in patients with neutropenia and cancer: results of a multicenter study.
Martino R; Rámila E; Capdevila JA; Planes A; Rovira M; Ortega Md ; Plumé G; Gómez L; Sierra J
Clin Infect Dis; 2001 Aug; 33(4):E20-2. PubMed ID: 11462207
[TBL] [Abstract][Full Text] [Related]
35. Perils of quinolone exposure in cancer patients: breakthrough bacteremia with multidrug-resistant organisms.
Rangaraj G; Granwehr BP; Jiang Y; Hachem R; Raad I
Cancer; 2010 Feb; 116(4):967-73. PubMed ID: 20052728
[TBL] [Abstract][Full Text] [Related]
36. Risk factors for mortality and clinical implications of catheter-related infections in patients with bacteraemia caused by Stenotrophomonas maltophilia.
Cheong HS; Lee JA; Kang CI; Chung DR; Peck KR; Kim ES; Lee JS; Son JS; Lee NY; Song JH
Int J Antimicrob Agents; 2008 Dec; 32(6):538-40. PubMed ID: 18715768
[No Abstract] [Full Text] [Related]
37. Stenotrophomonas maltophilia bacteraemia in Turkish children.
Güriz H; Ciftçi E; Ayberkin E; Aysev D; Ince E; Arsan S; Yavuz G; Doğru U
Ann Trop Paediatr; 2008 Jun; 28(2):129-36. PubMed ID: 18510823
[TBL] [Abstract][Full Text] [Related]
38. Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia bacteremia.
Lai CH; Chi CY; Chen HP; Chen TL; Lai CJ; Fung CP; Yu KW; Wong WW; Liu CY
J Microbiol Immunol Infect; 2004 Dec; 37(6):350-8. PubMed ID: 15599467
[TBL] [Abstract][Full Text] [Related]
39. Susceptibility to antimicrobial agents of Stenotrophomonas maltophilia isolated from patients with cancer and bacteremia.
Krcmery V; Trupl J; Svetlansky I
Clin Infect Dis; 2001 Jun; 32(11):1656. PubMed ID: 11340542
[No Abstract] [Full Text] [Related]
40. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes.
Vidal F; Mensa J; Almela M; Martínez JA; Marco F; Casals C; Gatell JM; Soriano E; Jimenez de Anta MT
Arch Intern Med; 1996 Oct; 156(18):2121-6. PubMed ID: 8862105
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
